Treatment strategies and mortality risk factors in patients with multidrug-resistant Acinetobacter baumannii pneumonia: A retrospective analysis.
Investigación Clínica · 05.03.2026 · 67 (1) · 108
DOI: 10.54817/ic.v67n1a08 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigación Clínica, online erschienen am 05.03.2026. Verfasst von Lili Liu und 3 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
This study aimed to investigate the determinants of drug resis-tance risk factors, 30-day all-cause mortality risk factors, and related clinical treatment strategies in patients with multidrug-resistant Acinetobacter bauman-nii (MDRAB) pneumonia. This retrospective study analyzed data from 168 pa-tients with MDRAB pneumonia and 141 patients with non-MDRAB pneumonia between February 2022 and February 2025. On the second day of admission, the severity of illness and use of carbapenems, tigecycline, etc., were higher in MDR-AB pneumonia patients than in non-MDRAB pneumonia patients (p
Zitieren
APA
Liu, L., Lu, W., Fang, G., & Zhang, W. (2026). Treatment strategies and mortality risk factors in patients with multidrug-resistant Acinetobacter baumannii pneumonia: A retrospective analysis. Investigación Clínica, 67(1), 108. https://doi.org/10.54817/ic.v67n1a08
Vancouver
Liu L, Lu W, Fang G, Zhang W. Treatment strategies and mortality risk factors in patients with multidrug-resistant Acinetobacter baumannii pneumonia: A retrospective analysis. Investigación Clínica. 2026;67(1):108. doi:10.54817/ic.v67n1a08
BibTeX
@article{Liu2026,
author = {Liu, Lili and Lu, Wen and Fang, Gege and Zhang, Wei},
title = {Treatment strategies and mortality risk factors in patients with multidrug-resistant Acinetobacter baumannii pneumonia: A retrospective analysis},
journal = {Investigación Clínica},
year = {2026},
volume = {67},
number = {1},
pages = {108},
doi = {10.54817/ic.v67n1a08}
}
EUVIMED